Researchers have found that a new FOLFOX4 regimen significantly improves outcomes for patients with advanced colorectal cancer, leading to longer survival times and reduced side effects. The regimen has been shown to extend median patient survival by four months and reduce tumor progression time.
Researchers evaluated 407 patients who had surgery to remove their cancer and were at high risk for recurrence. The study found no significant difference between radiation alone and chemotherapy plus radiation in reducing cancer recurrence or improving overall survival rates.
Researchers have developed a new breast cancer therapy that combines heat therapy, chemotherapy, and fat liposomes to deliver drugs directly to tumors. The treatment has shown promising results, destroying tumors and saving patients' breasts from surgical removal.
A study by Philip Breitfeld shows that initial hospital treatment costs can top $75,000 per child, but the average cost per year of life saved is just $2,700. Insurers lack access to data to justify spending on curative cancer therapies, leading to denied payments for high-priced procedures.